文章核心观点 - 公司收购GQ Bio剩余81%股权 推进成为创新生物制药组织的进程 并带来预期财务效益 [1] 交易概述 - 公司以约3200万美元收购GQ Bio剩余81%股权 净购买价含1800万美元现金、800万美元三年分期支付及600万美元交割后留存 [1] - 交易基于公司此前对GQ Bio的投资及双方合作 旨在开发PCRX - 201等产品 [1] GQ Bio情况 - GQ Bio是私有生物制药公司 拥有高容量腺病毒基因治疗载体平台 能使基因药物更高效 并带来临床前资产组合和研发人才 [2][12] - GQ Bio总部位于德国汉堡 在德国和比利时有站点 致力于开发慢性疾病的变革性疗法 [12] 公司战略与预期 - 公司CEO认为交易将增强满足患者需求的能力 推进5x30计划 且HCAd平台有潜力使公司成为肌肉骨骼疼痛治疗的领先开发者 [3] - 公司计划维持GQ Bio运营 投资其HCAd平台及相关创新产品 利用自身临床、监管和商业能力 [4] 财务效益 - 交易消除公司高达6400万美元的潜在未来里程碑付款义务 包括PCRX - 201二期临床试验启动时的450万美元里程碑付款 [5] HCAd平台特点 - HCAd平台解决基因医学领域诸多挑战 具有高容量、局部递送等特点 可开发针对肌肉骨骼疾病的基因药物 [6] - 与其他基因疗法相比 HCAd载体基因递送效率更高 能携带更多DNA 可局部给药和重新给药 且生产成本有商业吸引力 [7] HCAd产品线情况 - PCRX - 201基于HCAd设计 用于膝关节骨关节炎临床开发 可减少慢性炎症 且有炎症响应启动子 [8] - 2024年11月PCRX - 201一期大样本研究数据显示 其能持续改善膝关节疼痛、僵硬和功能 安全性良好 公司正准备启动二期随机双盲研究 [9] - 除临床前候选产品 双方还确定了众多可用于基于HCAd平台局部给药基因疗法的细胞因子 [10] 公司现有业务 - 公司有三款商业阶段非阿片类疼痛治疗产品 EXPAREL、ZILRETTA和iovera 还在推进PCRX - 201开发 [11]

文章核心观点 - 罗森律师事务所提醒2023年8月2日至2024年8月8日期间购买Pacira BioSciences公司证券的投资者2025年3月14日的首席原告截止日期，投资者或可获赔偿 [1] 后续行动 - 加入Pacira集体诉讼可访问https://rosenlegal.com/submit-form/?case_id=33570 或致电866 - 767 - 3653或发邮件至[email protected] [2][5] - 若想担任首席原告，必须不迟于2025年3月14日向法院提出申请 [2] 选择罗森律师事务所的原因 - 罗森律师事务所代表全球投资者，专注证券集体诉讼和股东派生诉讼 [3] - 该律所曾达成当时针对中国公司的最大证券集体诉讼和解协议 [3] - 2017年被ISS证券集体诉讼服务机构评为证券集体诉讼和解数量第一，2013年以来每年排名前四，为投资者追回数亿美元 [3] - 2019年为投资者追回超4.38亿美元，2020年创始合伙人被law360评为原告律师界巨头，多位律师获认可 [3] 案件详情 - 诉讼称在相关期间Pacira公司的陈述虚假或具误导性，其营造出对Exparel有足够专利保护的假象 [4] - 实际上Pacira公司知道'495专利不如公开宣称的有保护力，但仍公开肯定该专利 [4] - 当真相进入市场，投资者遭受损失 [4]

公司动态 - 法鲁奇&法鲁奇律师事务所正调查针对帕西拉生物科学公司的潜在索赔，并提醒投资者3月14日2025年是在针对该公司的联邦证券集体诉讼中争取首席原告角色的截止日期 [2] - 帕西拉在2024年8月9日宣布新泽西地方法院判定其'495专利无效，法院认为eVenus基于显而易见性和预期性不侵犯'495专利，该裁决在帕西拉提交额外证据后不久作出，且法院称该证据不影响判决依据，此裁决还与同一法院对帕西拉'495和'336专利有利于eVenus的权利要求解释裁决有关 [4] - 帕西拉'495专利无效的消息令投资者和分析师惊讶，其普通股股价从2024年8月8日收盘价22.36美元/股跌至8月9日最低价11.70美元/股，单日跌幅超47%，损害了投资者利益 [5] 投资者相关 - 法鲁奇&法鲁奇律师事务所证券诉讼合伙人詹姆斯（乔希）·威尔逊鼓励在2023年8月2日至2024年8月8日期间在帕西拉损失超75000美元的投资者直接联系他讨论选择 [1] - 法院指定的首席原告是在集体寻求的救济中具有最大经济利益、能代表集体成员且合适典型的投资者，其代表假定集体指导和监督诉讼，假定集体成员可选择争取担任首席原告或不作为缺席集体成员，是否担任首席原告不影响分享任何赔偿的权利 [6] 信息征集与联系方式 - 法鲁奇&法鲁奇律师事务所鼓励任何有关帕西拉行为信息的人包括举报人、前员工、股东等联系该事务所 [7] - 了解帕西拉生物科学公司集体诉讼更多信息可访问www.faruqilaw.com/PCRX或直接致电法鲁奇&法鲁奇合伙人乔希·威尔逊，电话877 - 247 - 4292或212 - 983 - 9330（分机1310） [1][7]

NEW YORK, Feb. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX).Shareholders who purchased shares of PCRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/pacira-biosciences-inc-loss-submission-form/?id=132330&from=4CLASS PERIOD: Augus ...

PARSIPPANY, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: Raymond James 46th Annual Institutional Investors Conference on Wednesday, March 5th at 10:25AM ET.Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12th at 8 ...

Wall Street analysts expect Pacira (PCRX) to post quarterly earnings of $0.86 per share in its upcoming report, which indicates a year-over-year decline of 3.4%. Revenues are expected to be $184.01 million, up 1.5% from the year-ago quarter.The current level reflects an upward revision of 5.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Before a company reve ...

NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Pacira investors who were adversely affected by alleged securities fraud between August 2, 2023 and August 8, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/pacira-biosciences-inc-lawsui ...

NEW YORK, Feb. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX).Shareholders who purchased shares of PCRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/pacira-biosciences-inc-loss-submission-form/?id=131193&from=4CLASS PERIOD: Augus ...

NEW YORK, Feb. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Pacira investors who were adversely affected by alleged securities fraud between August 2, 2023 and August 8, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/pacira-biosciences-inc-lawsui ...

PARSIPPANY, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its fourth quarter and year ended December 31, 2024 financial results after the close of the U.S. markets on Thursday February 27, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to p ...